

July 22, 2010

To those concerned

R-Tech Ueno, Ltd.  
(Code No.4573, Osaka Securities Exchange; Hercules)  
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo  
Representative: Yukihiko Mashima, Representative Director & President  
Contact: Koji Nakamura, Business Management Department TEL:  
03-(3596) 8011

### Announcement of Change in Storage Condition for Rescula<sup>®</sup> Eye Drops 0.12%

R-Tech Ueno, Ltd. is announcing the following partial change with regard to the storage condition of Rescula<sup>®</sup> Eye Drops 0.12%.

As the developer of Rescula<sup>®</sup> Eye Drops 0.12%, R-Tech Ueno has been constantly seeking other technologies to improve this product from the standpoint of patients. On February 4, 2009, R-Tech Ueno received the approval for partial change into the formulation containing a reduced amount of the preservative of the product from Japan's Ministry of Health, Labour and Welfare.

We are pleased to inform you that R-Tech Ueno received the approval for partial change in the storage condition for Rescula<sup>®</sup> Eye Drops 0.12% from the Ministry of Health, Labour and Welfare on May 10, 2010. Until now, this product had to be stored in a cold place (1-15°C). However, starting with products that have the following lot number, the product can be stored at room temperature. There are no changes to the chemical composition or efficacy of Rescula<sup>®</sup> Eye Drops 0.12%.

Lot number and scheduled shipment dates of product with revised storage condition

Lot number:	071KD
Shipment dates:	Starting in July 2010

R-Tech Ueno will continue to conduct research programs with the goal of enabling Rescula<sup>®</sup> Eye Drops 0.12% to be used for the treatment of an even larger number of people.

About Rescula<sup>®</sup> Eye Drops 0.12%:

It is the first therapeutic drug for glaucoma and ocular hypertension in the world that contains prostone, a metabotropic prostaglandin derivative. Rescula<sup>®</sup> Eye Drops 0.12% has a pharmacological effect as an ion channel opener. There are reports that Rescula<sup>®</sup> Eye Drops 0.12% has not only an ocular pressure decreasing action but also an optic nerve protective action (*in vitro*) and an action to improve ocular blood flow in normal tension glaucoma. It has been approved in 45 countries all over the world since it was marketed in 1994. In 2009, due to formulation change, the concentration of the preservative (benzalkonium chloride) which is reported to cause various adverse reactions has been greatly reduced using our unique technique.

About R-Tech Ueno, Ltd.:

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of marketing and R&D of drugs. Under leadership of the president, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and selling and developing pharmaceutical products through the eyes of doctors.” We are promoting development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

The company's main product Rescula® Eye Drops 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance “prostone” in the development of Rescula®. Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company.

Rescula® Eye Drops 0.12% that causes less topical and systemic adverse reactions, demonstrates steady ocular pressure decreasing action by twice a day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow increasing mechanism.